Endocare And Galil Relations Cold As Prostate Cryosurgery Market Heats Up
This article was originally published in The Gray Sheet
Executive Summary
The number of cryoablation procedures to treat prostate cancer is expected to grow more than 100% over the next year, fueled by favorable outcomes from a five-year study evaluating Endocare's Cryocare system, the company predicts.
You may also be interested in...
Endocare Eyes Niche Market In Prostate Cancer Salvage Therapy
Endocare's request for Medicare coverage of cryosurgery to treat prostate cancer radiation-therapy "salvage" patients likely will not be referred to the Medicare Coverage Advisory Committee, according to the Health Care Financing Administration.
Endocare Eyes Niche Market In Prostate Cancer Salvage Therapy
Endocare's request for Medicare coverage of cryosurgery to treat prostate cancer radiation-therapy "salvage" patients likely will not be referred to the Medicare Coverage Advisory Committee, according to the Health Care Financing Administration.
EndoCare's Cryocare Gets National Medicare Coverage Nod From HCFA
The Health Care Financing Administration will allow Medicare payment for cryosurgery for prostate cancer, citing data submitted by EndoCare, maker of the Cryocare system for cryosurgical ablation, the company reports.